Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-007 in Advanced Colorectal and Gastric Cancer
NCT03253185Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2017
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SC-007 in colorectal cancer (CRC) and gastric cancer (GC), sponsored by AbbVie Inc. Primary endpoint: Number of participants with dose-limiting toxicities at 21 days. Started Sep 2017; status: terminated.
02
Drugs
SC-007
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03253185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253185.